RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

I'm not sure how your "taking full blame" and feeling "hate" go together. But that's your problem.

Since you asked, I took a look back at what has been definitively proven 'wrong', and what remains to be seen.

Definitively, absolutely wrong:
Expecting that the FDA's Psychiatry Division would give the OK for the ADHD Phase IIb trial to go ahead when the artifact was shown to be post-mortem. As illogical or wrongheaded as I may think that to have been, that was an incorrect read of Thomas Laughren, and that has never stopped reverberating.

Probably wrong:
Expecting that the RD results would produce a partnership. It's possible, but with SA results nigh, I think the likelihood of a RD-only deal is tiny. As I have discussed here (I believe in response to a good question by Blade), that probably relates to the lack of data for IV CX717 or oral CX01739, and the difficulty of designing Phase IIb.

Yet to be determined:
SA trial success or failure
SA partnership
ADHD partnership

Those factors, singly or together, would have more than a little impact upon Cortex's valuation and share price, and until the fate of any or all of them is known, you are rushing to judgment.

I personally will wait until the end of the 9th inning before declaring who won or lost the game--if there is a good reason to not do so, make the case. If people have alternative hypotheses for how any of these factors may play out or influence the value of the Company, as I have said before, that would be of interest to me and others.


NeuroInvestment